Theradigm-HBV peptide-based therapeutic vaccine data

CYTL reported interim results of one of two ongoing Phase II trials of its therapeutic vaccine, showing that Theradigm-HBV stimulated an HBV-specific cytotoxic T lymphocyte (CTL) response in chronically infected patients.

The data, presented at the Industry Congress on Hepatitis in Washington, are based on 27 patients treated in an open-label, dose-escalation trial. Patients received Theradigm-HBV in a single injection of 50, 500 or 5,000 µg, followed in six weeks by a single booster of the same dose. ...